Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $511.08 USD
Change Today +4.57 / 0.90%
Volume 374.9K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert J. Terifay

Senior Vice President of Commercial, Regeneron Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

55$8,396,327
As of Fiscal Year 2014

Background*

Mr. Robert J. Terifay has been a Senior Vice President of Commercial at Regeneron Pharmaceuticals, Inc. since February 26, 2007. Prior to Regeneron, Mr. Terifay served as the President and Chief Operating Officer at Arginox Pharmaceuticals, Inc from January 2006 to October 2006. He has more than 20 years of experience in the life science industry and has experience in commercial strategy and positioning new products for market-entry in the pharmaceutical industry. Prior ...

Read Full Background

Corporate Headquarters*

777 Old Saw Mill River Road
Tarrytown, New York 10591

United States

Phone: 914-847-7000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BS
University of Notre Dame
Master's Degree
J.L. Kellogg School of Management, Northwestern University

Other Affiliations*

Annual Compensation*

Salary$465,800
Bonus$377,298
Total Annual Compensation$843,098

Stock Options*

All Other Compensation$20,125
Exercised Options76,545
Exercised Options Value$26,944,855
Exercisable Options204,375
Exercisable Options Value$67,453,713
Unexercisable Options123,125
Unexercisable Options Value$17,244,388
Total Value of Options$111,642,955
Total Number of Options404,045

Total Compensation*

Total Annual Cash Compensation$863,223
Total Short Term Compensation$843,098
Other Long Term Compensation$20,125
Total Calculated Compensation$8,396,327
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $511.08 USD +4.57

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jean-Jacques Bienaime MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
$916.0K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.1M
Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
$2.9M
Nobuo Hanai Ph.D.Chief Executive Officer, President and Representative Director
Kyowa Hakko Kirin Co., Ltd.
--
Jean-Christophe Tellier Chief Executive Officer and Executive Director
UCB S.A.
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.